If you think you may have symptoms of coronavirus (opens in new window) >, follow the national guidance and self-isolate for 10 days. Please see our information for visitors > before you plan on visiting one of our hospitals. If you, or a member of your family has tested positive for coronavirus, please find resources to aid your/their recovery on our supporting your recovery from coronavirus > page.
Participants will have renal MRI performed at study entry and again after 2 years. Renal function and albuminuria will be collected at annual follow up visits, and biosamples (plasma, serum, urine and DNA) collected at baseline. Long term follow up data will be collected for 10 years via the UK Renal Registry.
Nine centres are taking part: Nottingham-Derby; Glasgow; Edinburgh; Newcastle; Sheffield; Leeds; Salford-Manchester; University College London; and Cambridge. These centres are part of the UK Renal Imaging Network (opens in new window) > (UKRIN), and the AFiRM study will build on work already in progress within a Medical Research Council funded project called UKRIN-MAPS (opens in new window) >. UKRIN-MAPS will standardise the way multiparametric MRI scans are performed across different MRI scanners and sites.
AFIRM starts in September 2020 and will continue for 7 years.
The study has three stages to address the following objectives:
This study will build on UK investments in renal MRI to generate reliable data that will advance the translation of renal MRI to clinical practice. Outputs will underpin improvements in patient care, substantially broaden research activity and lay foundations for industry collaborations. Multiparametric renal MRI has the potential to transform the development of novel drugs to reduce CKD progression by providing a new means for patient selection (identification of people with mechanisms of CKD progression that are appropriate to the drug being tested) and new measures to detect response to therapy earlier than traditional clinical outcome measures. Dissemination will target a range of stakeholders including clinicians, academic groups, industry, patients and the public to maximise impact of the research.
The study has three stages:
An internal pilot study to demonstrate feasibility of performing the MRIs at each of the centres (5 participants per site).
Following successful completion of Stage 1, the study will recruit a total of 450 participants across 9 centres in the UK.
In Stage 2, a minimum of 45 participants will have renal biopsy samples analysed using quantitative immunohistochemistry that will be compared against MRI measures.